Design of a novel cognitive enhancer (8S, 10aS)-8-carbamoyl-1,2,3,6,7,8,9,10a-octahydro-5H,10H-pyrrolo[1,2a][1,4 ]diazocin-5,10-dione

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 21, 1996, Pages 2595-2600

  Mazurov, Anatoly A ^a   Andronati, Sergei A ^b   Korotenko, Tamara I ^b   Sokolenko, Nikolai I ^b   Dyadenko, Alexei I ^b   Shapiro, Yuri E ^b   Gorbatyuk, Vitalii Ya ^b   Voronina, Tatyana A ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

8 CARBAMOYL 1,2,3,6,7,8,9,10A OCTAHYDRO 5H,10H PYRROLO[1,2 A][1,4]DIAZOCIN 5,10 DIONE; NOOTROPIC AGENT; OXIRACETAM; PYRROLE DERIVATIVE; PYRROLO[1,2 A][1,4]DIAZOCIN DERIVATIVE; UNCLASSIFIED DRUG;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR OVERHAUSER EFFECT; RAT;

ANIMALIA;

EID: 0030571281     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00478-7     Document Type: Article

References (33)

1. 1. Metcalf, G.; Dettmar, P. W. Lancet 1981, 1, 586.
2. 2. Yarbrough, G. Life Sci. 1983, 33, 111.
3. 3. Stwertka, S. A.; Vincent, G. P.; Gamzu, E. R.; MacNeil. D. A.; Vederese, A. Pharmacol. Biochem. Behav. 1991, 41, 145.
4. 4. (a) Yarbrough, G.; Pomara, M. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1985, 9, 285.
5. (b) Miyamoto, M.; Yamazaki, N.; Nagaoka, A.; Nigawa, Y. Ann. N.Y. Acad. Sci. 1989, 508.
6. 5. Crick, F. H. C. J. Mol. Biol. 1966, 19, 548.
7. 6. Zasloff, M. Proc. Natl. Acad. Sci. USA 1987, 84, 5449.
8. 7. (a) Guillemin, R.; Brazeau, P.; Böhlen, P.; Esch, F.; Ling, N.; Wehrenberg, W. B. Science 1982, 218, 585.
9. (b) Spiess, J.; Rivier, J.; Vale, W. Nature 1983, 303, 532.
10. 8. Potts, Jr., J. T. In Peptides Hormones; Parsons, J. A., M. A., B. M., B. Ch. Eds.; University Park Press: Baltimore, London, Tokyo, 1976; p. 134.
11. 9. Schröder, E.; Lübke, K. The Peptides, Vol. II; Academic Press: New York and London, 1966; pp. 52.
12. 10. (a) Mazurov, A. A.; Andronati, S. A.; Kabanov, V. M.; Sokolenko, N. I.; Rokachinskaya, M. G.; Shapiro, Yu. E.; Gorbatyuk, V. Ya. Collect. Czech. Chem. Commun. 1990, 55, 2555.
13. (b) Rokachinskaya, M. G.; Golovenko, N. Ya.; Kabanov, V. M.; Mazurov, A. A.; Andronati, S. A. Physiologically Active Compounds (Kiev) 1991, 23, 46.
14. 11. Shapiro, Yu. E.; Gorbatyuk, V. Ya.; Kabanov, V. M.; Mazurov, A. A.; Andronati, S. A.; Lobasyuk, B. A.; Golovenko, N. Ya.; Rokachinskaya, M. G. Sov. J. Bioorg. Chem. 1990,16, 1607.
15. 12. Mazurov, A. A.; Andronati, S. A.; Lobasyuk, B. A.; Kabanov, V. M.; Korotenko, T. I. Pharm. Chem. J. 1988, 155.
16. 13. Gorbatyuk, V. Ya.; Shapiro, Yu. E.; Mazurov, A. A.; Zhuravlyov, V. G.; Andronati, S. A.; Korotenko, T. I.; Romanovsky, P. Ya. Sov. J. Bioorg. Chem. 1992, 18, 235.
17. 14. Peterson, R. E.; Guillemin, R. G. Amer. J. Med. 1974, 57, 591.
18. 15. TRH reversed ECS-induced amnesia on 23% in the dose of 0.1 mg/kg, while 2 was equipotent in the dose of 1 mg/kg.
19. carbamoxyl is 5.5 Å for 3.
20. 17. Mazurov, A.A.; Antonenko, S. V.; Andronati, S. A. Chemistry of Natural Compounds (USSR) 1986, 208.
21. 18. (a) Andronati, S. A.; Mazurov, A.A. Sov. J. Bioorg. Chem. 1984, 10, 1445.
22. (b) Andronati, S. A.; Mazurov, A.A.; Korotenko, T. I. Chemistry of Peptides and Proteins 1986, 3, 37.
23. 19. Porsolt, R. D.; Anton, G.; Blavet, N.; Jalfre, M. Eur. J. Pharmacol. 1978, 47, 379.
24. 20. Banfi, S.; Cornelli, U.; Fonio, W.; Dorigotti, L. J. Pharmacol. Methods 1982, 8, 255.
25. 21. Pozzi, O.; Allievi, E.; Biagetti, R.; Banfi, S.; Dorigotti, L. Pharmacol. Res. Commun. 1988, 20 (Suppl. 2), 315.
26. 22. No statistically significant differences between control and experiment were revealed at doses 1.0 - 0.001 mg/kg.
27. 23. Schindler, U.; Rush, D. K.; Fielding, S. Drugs Develop. Res. 1984, 4, 567.
28. 24. Verloes, R.; Scotto, A. M.; Gobert, J.; Wülfert, E. Psychopharmacology 1988, 95, 226.
29. 25. Pinza, M.; Farina, C.; Cerri, A.; Pfeiffer, U.; Riccaboni, M. T.; Banfi, S.; Biagetti, R.; Pozzi, O.; Magnani, M.; Dorigotti, L. J. Med. Chem. 1993, 36, 4214.
30. 26. Antihypoxic effect was studied using the model of acute hypobaric hypoxia in flowthrough low pressure chamber model (Korablyov, M. V.; Lukienko, P. I. Antihypoxic Compounds; 1976, Minsk, Naukova Dumka, p.334). Experiments were carried out on male rats. The animals in experimental group (16 rats) were administered (ip) solution of the compound at 10 min before experiment. The animals in control group (16 rats) were injected saline. Groups of 4 animals were "lifted" with the speed 1 km/min to the platform with the "height" of 11 km. Animals were kept on this platform for 15 min and then put down with the speed 3.7 km/min. Ascent to high altitude was simulated experimentally by exposure of rats in chamber to a breathing air at alterable pressure. 56% of animals survived in experimental group in comparison with 18% in control group.
31. 27. For detection of neurological deficit, myorelaxant and sedative action, motor impairment, psychomotor activation were investigated in rolling roller test (Dunham, N. W.; Miya, T. S. J. Amer. Pharm. Assoc. 1957, 46, 208), traction test ( Boissier, J.-R.; Dumont, C.; Ratouis, R.; Pagny, J. Arch. Int. Pharmacodyn. 1961, 133, 29 ) and open field test (Boissier, J.-R.; Simon, P. Thérapie 1962, 17, 1225).
32. 27. For detection of neurological deficit, myorelaxant and sedative action, motor impairment, psychomotor activation were investigated in rolling roller test (Dunham, N. W.; Miya, T. S. J. Amer. Pharm. Assoc. 1957, 46, 208), traction test ( Boissier, J.-R.; Dumont, C.; Ratouis, R.; Pagny, J. Arch. Int. Pharmacodyn. 1961, 133, 29 ) and open field test (Boissier, J.-R.; Simon, P. Thérapie 1962, 17, 1225).
33. 27. For detection of neurological deficit, myorelaxant and sedative action, motor impairment, psychomotor activation were investigated in rolling roller test (Dunham, N. W.; Miya, T. S. J. Amer. Pharm. Assoc. 1957, 46, 208), traction test ( Boissier, J.-R.; Dumont, C.; Ratouis, R.; Pagny, J. Arch. Int. Pharmacodyn. 1961, 133, 29 ) and open field test (Boissier, J.-R.; Simon, P. Thérapie 1962, 17, 1225).